Lisata Therapeutics had its Annual Meeting, voting on new directors and plans, but postponed a key stock proposal.

Nov 9, 2026, 5:24 PM ETPaperworkRead the original at SEC EDGAR

Neutral

LSTA approved a reverse split and two share plans, but postponed a vote on a conversion that could issue more than 20% of its shares and change control. That ownership decision remains pending, so the filing does not settle the company's outlook.

LSTA · Lisata Therapeutics, Inc.

AI read · Neutral

The AI's read

The conversion vote matters because approval would allow shares representing more than 20% of LSTA's common shares to be issued and could change control. Stockholders have not voted on it yet. The reverse-split approval gives the board a choice of split size without reducing authorized shares, but no split or conversion has taken effect. The other approved items are board, auditor, and employee-share matters, not reported business results.

Get alerts for LSTA

Follow Lisata Therapeutics, Inc. (LSTA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LSTA

Free on the App Store and Google Play, or on the web.